Avid Bioservices Inc (CDMO)

[cjgaddy]

7-14-17: Avid Scientists have developed “Antibody Discovery Platform” - applicable to Avid’s customer offerings and Peregrine’s drug dev. R&D side. Looks like good potential – SK calls it a “platform”, and it hit the 10-K. Most interesting (to me).

7-14-17/CEO Steve King: “Another part of our effort to attract new customers is to expand our service offerings. Our scientists have developed a state-of-the-art Antibody Discovery & Characterization Platform through which we can generate antibodies against virtually any target. These capabilities are meant to allow rapid screening for high affinity antibodies that are developable. These capabilities are a natural extension of the services we already offer through Avid and it represents an attractive way to bringing customers at a much earlier stage of development with the potential to move them quickly into process developments and cGMP manufacturing.”...
“The Antibody Discovery Platform discussed earlier [Avid] could also be instrumental on the R&D side of the business, allowing us to rapidly identify antibodies against already validated targets, as well as the potential to identify novel targets. As we think about diversifying our development pipeline to include lower risk, already validated targets, this new capability could help us to identify developable antibodies that could have short-term value, as the need for such antibodies is on the rise. And this approach fits very well into our core capabilities and experience in the development of monoclonal antibodies. You can expect to hear more about this new capability over the coming months on both sides of our business.” http://tinyurl.com/yb4wulvu

4-30-17 10-K pub. 7-14-17 pg.5:
Antibody Discovery Technology
“Recently, our scientists have developed an Antibody Discovery & Characterization Platform through which we can generate antibodies against virtually any target. These capabilities are state-of-the-art and meant for rapid screening for high affinity antibodies as drug candidates. These capabilities are a natural extension of the services we already offer through Avid and it may represent a way to bring in customers at a much earlier stage of development with the potential to move them quickly into process development and cGMP manufacturing. Continuing to diversify our customer base is one of our key initiatives at Avid and we believe the antibody discovery capabilities will help attract new customers. The antibody discovery capabilities can also be used in our R&D business to rapidly identify antibodies against known targets as well as to identify novel targets. The antibody discovery platform is now fully functional and we are in the process of evaluating the technology through identifying several known targets and thus far, the results have looked promising. Once this process is completed, the technology platform will be marketed to potential customers as part of our CDMO service offerings.” http://tinyurl.com/ycxu4l5n